Cargando…

Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy

BACKGROUND: The tumor microenvironment is associated with prognosis in advanced non‐small cell lung carcinoma (NSCLC). The aim of this study was to explore the relationship between blood T cell diversity and survival of patients treated with pemetrexed‐based chemotherapy for nonsquamous NSCLC. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Li, Zhaohui, Zhang, Yaping, Xu, Zhentian, Liu, Zhentao, Liu, Qiqi, Wang, Yangchun, Gu, Yan'e, Liu, Wencheng, Yin, Fumei, Yi, Yanhong, Yao, Baoshan, Cao, Li, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017263/ https://www.ncbi.nlm.nih.gov/pubmed/33626215 http://dx.doi.org/10.1111/1759-7714.13771

Ejemplares similares

Characteristics and Clinical Implication of UGT1A1 Heterozygous Mutation in Tumor
por: LI, Qian, et al.
Publicado: (2022)

Analysis of pemetrexed-based chemotherapy in the treatment of advanced colorectal cancer
por: Yu, Zhengyi, et al.
Publicado: (2020)

Clinical value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma
por: Guo, Ziwei, et al.
Publicado: (2017)

A Novel Circular RNA circPTCD3 Promotes Breast Cancer Progression Through Sponging miR-198
por: Zhang, Zhaohui, et al.
Publicado: (2021)

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
por: Jo, Jaemin, et al.
Publicado: (2018)

Successful immune checkpoint inhibitor‐based rechallenge in a patient with advanced esophageal squamous cell cancer: A case report
por: Yao, Yanhong, et al.
Publicado: (2022)

PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed
por: Zhang, Pei, et al.
Publicado: (2017)

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro
por: Feng, Xiuli, et al.
Publicado: (2017)

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007)

Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts
por: Cui, Jiadong, et al.
Publicado: (2018)

Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines
por: Monica, Valentina, et al.
Publicado: (2016)

First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer
por: Shen, Lan, et al.
Publicado: (2020)

Pemetrexed plus dendritic cells as third-line therapy for metastatic esophageal squamous cell carcinoma
por: Zhang, Bin, et al.
Publicado: (2016)

Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules
por: Li, K M, et al.
Publicado: (2007)

Single pemetrexed is noninferior to platinum-based pemetrexed doublet as first-line treatment on elderly Chinese patients with advanced nonsquamous nonsmall cell lung cancer
por: Pu, Xiaolin, et al.
Publicado: (2017)

Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy
por: MOU, WENJUN, et al.
Publicado: (2014)

Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo
por: Liu, Tianze, et al.
Publicado: (2019)

Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
por: Zhang, Limin, et al.
Publicado: (2016)

Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis
por: Li, Zhihua, et al.
Publicado: (2018)

A Case of Metastatic Urothelial Carcinoma Treated with Pemetrexed as Third-Line Chemotherapy with Discussion and Literature Review
por: Iida, Keitaro, et al.
Publicado: (2015)

High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy
por: Gota, Vikram, et al.
Publicado: (2014)

Epiphora following chemotherapy with pemetrexed in patients with advanced non-small cell lung cancer
por: Jung, Yun Duk, et al.
Publicado: (2017)

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
por: Lu, Shun, et al.
Publicado: (2016)

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
por: Wang, Yan, et al.
Publicado: (2018)

Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
por: Liu, Huiqin, et al.
Publicado: (2022)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
por: Maharjan, Ruby, et al.
Publicado: (2019)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
por: Felip, Enriqueta, et al.
Publicado: (2008)

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
por: Ricciardi, Serena, et al.
Publicado: (2009)

Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations
por: Li, Jing, et al.
Publicado: (2016)

Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer
por: Shi, Yafei, et al.
Publicado: (2023)

Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
por: Liu, Huiqin, et al.
Publicado: (2023)

Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer
por: Chen, Xiaoxia, et al.
Publicado: (2020)

Pemetrexed-associated Ischemic Colitis in Nonsmall Cell Lung Cancer
por: Ye, Liang, et al.
Publicado: (2017)

Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center ambispective cohort study
por: Gu, Yangchun, et al.
Publicado: (2023)

Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature review
por: He, Guangzhao, et al.
Publicado: (2016)

Serum Protein Pattern Could Predict the Therapeutic Effect of First-Line Pemetrexed/Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma
por: Shen, Hong, et al.
Publicado: (2015)

The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis
por: Zhong, Anyuan, et al.
Publicado: (2015)

First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China
por: Qi, Fei, et al.
Publicado: (2019)

Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines
por: Nannizzi, Sara, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_61eh406c22b1npof2s4s52jsta